Europe 1 with AFP 3:49 p.m., March 29, 2022
The European Medicines Agency (EMA) announced on Tuesday the launch of the review procedure for the Covid-19 vaccine from the Spanish multinational HIPRA, indicating that it seemed effective against the Omicron variant.
A new vaccine under study.
The European Medicines Agency (EMA) announced on Tuesday the launch of the review procedure for the Covid-19 vaccine from the Spanish multinational HIPRA, indicating that it appeared to be effective against the Omicron variant.
"Preliminary results suggest that the immune response to the Spanish HIPRA vaccine may be effective against SARS-Cov-2, including variants that are of concern such as Omicron," said an EMA statement.
Soon a sixth vaccine?
On the Agency's website, it is stated that it will assess the data "as soon as it becomes available to decide whether the benefits outweigh the risks. Ongoing review will continue until sufficient evidence is available for a formal marketing authorization application.
Subsequently, if this request is validated, the HIPRA vaccine will be part of the list of the various vaccines available in Europe, such as the Pfizer-BioNTech, Moderna, AstraZeneca, Janssen and Novavax vaccines.
For its part, the French laboratory Sanofi is still waiting for a green light to market its vaccine, the intermediate results of which were deemed positive by its teams last September.